iTeos Therapeutics/$ITOS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About iTeos Therapeutics
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
Ticker
$ITOS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
173
ISIN
US46565G1040
Website
ITOS Metrics
BasicAdvanced
$395M
-
-$3.09
1.43
-
Price and volume
Market cap
$395M
Beta
1.43
52-week high
$18.13
52-week low
$4.80
Average daily volume
882K
Financial strength
Current ratio
14.133
Quick ratio
13.78
Long term debt to equity
0.646
Total debt to equity
0.897
Profitability
EBITDA (TTM)
-148.649
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-373.75%
Operating margin (TTM)
-428.31%
Effective tax rate (TTM)
-10.99%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
-14.54%
Return on equity (TTM)
-23.68%
Valuation
Price to revenue (TTM)
12.467
Price to book
0.7
Price to tangible book (TTM)
0.7
Price to free cash flow (TTM)
-4.349
Free cash flow yield (TTM)
-22.99%
Free cash flow per share (TTM)
-237.06%
Growth
Earnings per share change (TTM)
-18.24%
3-year revenue growth (CAGR)
-58.71%
3-year earnings per share growth (CAGR)
-26.31%
What the Analysts think about ITOS
Analyst ratings (Buy, Hold, Sell) for iTeos Therapeutics stock.
Bulls say / Bears say
iTeos Therapeutics maintains a strong cash position of $624.3 million as of March 31, 2025, providing financial stability and runway through 2027. (iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates)
The company is exploring potential asset sales, including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1, which could unlock shareholder value. (iTeos Therapeutics Announces Intent to Wind Down Operations and Explore Asset Sales to Maximize Shareholder Value)
Institutional investors like RA Capital Management and Boxer Capital have shown confidence by leading a $120 million registered direct offering, strengthening iTeos' financial position. (iTeos Therapeutics Announces $120 Million Registered Direct Offering)
iTeos and GSK have terminated the development of their experimental lung cancer therapy, belrestotug, after it failed to significantly improve progression-free survival in mid-stage trials. (iTeos, GSK discontinue lung cancer therapy development)
The company has announced its intention to wind down operations, focusing on selecting the best path to deliver near-term value to shareholders, indicating potential challenges in its pipeline. (iTeos Therapeutics Announces Its Intention to Wind Down Operations)
JPMorgan Chase & Co. has lowered its price target for iTeos Therapeutics from $22.00 to $15.00, reflecting reduced expectations for the company's stock performance. (JPMorgan Chase & Co. Has Lowered Expectations for iTeos Therapeutics (NASDAQ:ITOS) Stock Price)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
ITOS Financial Performance
Revenues and expenses
ITOS Earnings Performance
Company profitability
ITOS News
AllArticlesVideos
iTeos Therapeutics Announces Its Intention to Wind Down Operations
GlobeNewsWire·2 months ago
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
GlobeNewsWire·2 months ago
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for iTeos Therapeutics stock?
iTeos Therapeutics (ITOS) has a market cap of $395M as of July 16, 2025.
What is the P/E ratio for iTeos Therapeutics stock?
The price to earnings (P/E) ratio for iTeos Therapeutics (ITOS) stock is 0 as of July 16, 2025.
Does iTeos Therapeutics stock pay dividends?
No, iTeos Therapeutics (ITOS) stock does not pay dividends to its shareholders as of July 16, 2025.
When is the next iTeos Therapeutics dividend payment date?
iTeos Therapeutics (ITOS) stock does not pay dividends to its shareholders.
What is the beta indicator for iTeos Therapeutics?
iTeos Therapeutics (ITOS) has a beta rating of 1.43. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.